Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. (June 2020)

• Record Type: Journal Article
• Authors: Peters, Solange; Shaw, Alice T.; Besse, Benjamin; Felip, Enriqueta; Solomon, Benjamin J.; Soo, Ross A.; Bearz, Alessandra; Gadgeel, Shirish M.; Lin, Chia-Chi; Kao, Steven; Seto, Takashi; Masters, Elizabeth T.; Abbattista, Antonello; Clancy, Jill S.; Thurm, Holger; Reisman, Arlene; Peltz, Gerson; Ross Camidge, D.
• Is Part Of: Lung cancer. Volume 144(2020)
• Page Start: 10
• Page End: 19
• Publication Date: 2020-06
• Subjects: ALK -- Lorlatinib -- NSCLC -- Patient-reported outcomes -- QoL -- ROS1; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2020.02.011
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: QoL measures have increasingly been used as end points in clinical studies. Lorlatinib is approved in Japan, USA, EU, and Canada for ALK-positive metastatic NSCLC. Global QoL and functioning showed meaningful improvement or stability in most patients. Disease-related symptoms similarly improved in most patients. Improvements in PROs were maintained over time. Abstract: Objectives: To evaluate patient-reported outcomes (PROs) from a phase 1/2 study (NCT01970865) in patients with anaplastic lymphoma kinase (ALK)- or ROS1-positive advanced non-small cell lung cancer (NSCLC) treated with lorlatinib 100 mg once daily. Materials and methods: PRO measures, including global quality of life (QoL), functioning domains and symptoms, were assessed by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and the 13-item Lung Cancer (QLQ-LC13) module. Mean changes of absolute scores from baseline were assessed. Percentages of patients showing improvement, stability or worsening on each scale were reported, with a change of ≥10 points considered clinically meaningful (CM). Results: 255 patients completed baseline and ≥1 post-baseline PRO assessment. Most patients had CM improvement (42.4 %) or stable (38.0 %) scores for global QoL. Functioning domains with the greatest proportion of patients with improved scores were role (37.6 %) and emotional (36.9 %); only one domain had more patients showing worsening than improving function (cognitive [24.3 % vs 22.4 %]). Most patients showed improved or stable scores for disease-related symptoms. No QLQ-C30 symptom domains had more patients worsening than improving. Symptoms on the QLQ-C30 scale with the greatest proportion of patients with improved scores were fatigue (49.4 %) and insomnia (46.3 %). Four QLQ-LC13 domains had more patients worsening than improving (two most affected were peripheral neuropathy [37.3 % vs 13.7 %] and alopecia [19.2 % vs 13.3 %]). Symptoms on the QLQ-LC13 scale with the greatest proportion of patients with improved scores were cough (42.7 %) and pain in other parts (32.9 %). Conclusions: Lorlatinib treatment showed CM improvement from baseline in global QOL that was maintained over time. Additionally, there were improvements in physical, emotional, social, and role functioning. Improvements were shown in appetite loss and key symptoms such as pain, dyspnea, cough and fatigue; a worsening in peripheral neuropathy was noted.